In cancer, EPI/NE in the TME predominantly activate pathways such as ERK/MAPK and cAMP/PKA via β2‐AR and other receptors, promoting tumor proliferation and metastasis (e.g., GC and CRC) while inhibiting only certain tumors, such as melanoma. This evidence concerns the gene MAPK1 and neoplasm.